Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT6A | Q92794 | 1/20 | 0.61 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.58 |
| ▸ | KMO | O15229 | 1/20 | 0.56 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.55 |
| ▸ | PDE4A | P27815 | 1/20 | 0.54 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.54 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.54 |
| ▸ | ERN1 | O75460 | 1/20 | 0.53 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | FNTA | P49354 | 1/20 | 0.52 |
| ▸ | FNTB | P49356 | 1/20 | 0.52 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17799599 | 0.98 | KAT6A (0.63) | KAT6APTGER1KMOMRGPRX4PDE4A | |
| Benzoic Acid SCHEMBL8917895 | 0.88 | RXRA (0.58) | KAT6ALMNAMAPK1HTTTDP1 | |
| SCHEMBL4063179 | 0.88 | STIM1 (0.64) | KAT6APTGER1KMOMRGPRX4PDE4A | |
| SCHEMBL3647093 | 0.87 | EGLN1 (0.52) | KAT6APTGER1ERN1TDP1EDNRB | |
| SCHEMBL5924712 | 0.87 | EGLN1 (0.52) | KAT6APTGER1ERN1TDP1EDNRB | |
| SCHEMBL14879938 | 0.86 | MRGPRX4 (0.54) | KAT6APTGER1KMOMRGPRX4PDE4A | |
| SCHEMBL3861503 | 0.86 | KAT6A (0.56) | KAT6APDE4DERN1PTPN5HTR7 | |
| SCHEMBL6082944 | 0.86 | KAT6A (0.60) | KAT6AERN1PTPN5NPC1RAB9A | |
| SCHEMBL4334719 | 0.85 | LMNA (0.54) | KAT6AMRGPRX4PDE4APDE4BPDE4C | |
| SCHEMBL28598178 | 0.84 | PTGER1 (0.62) | PTGER1KMOMRGPRX4LMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6011175-A | Inhibition of farnesyltransferase | UNIVERSITY OF PITTSBURGH (US) | 2000-01-04 | — | — | US | claimed |
| US-20260001846-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | SERVIER LAB (FR) | 2026-01-01 | — | — | US | disclosed |
| EP-4551566-A1 | NEW SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | Les Laboratoires Servier (FR) | 2025-05-14 | — | — | EP | disclosed |
| CN-117186001-B | AHA1 inhibitor with multiple myeloma-resisting activity and preparation method and application thereof | 南京中医药大学 | 2024-09-17 | — | — | CN | disclosed |
| WO-2024008941-A1 | NEW SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | LES LABORATOIRES SERVIER (FR) | 2024-01-11 | — | — | WO | disclosed |
| CN-117186001-A | AHA1 inhibitor with multiple myeloma-resisting activity and preparation method and application thereof | 南京中医药大学 | 2023-12-08 | — | — | CN | disclosed |
| EP-2607348-B1 | Plasminogen Activator Inhibitor-1 Inhibitor | RENASCIENCE INC (JP) | 2021-03-17 | — | — | EP | disclosed |
| EP-3174392-B1 | MOLECULES HAVING CERTAIN PESTICIDAL UTILITIES, AND INTERMEDIATES, COMPOSITIONS, AND PROCESSES RELATED THERETO | DOW AGROSCIENCES LLC (US) | 2020-03-18 | — | — | EP | disclosed |
| EP-3174392-A1 | MOLECULES HAVING CERTAIN PESTICIDAL UTILITIES, AND INTERMEDIATES, COMPOSITIONS, AND PROCESSES RELATED THERETO | Dow AgroSciences LLC (US) | 2017-06-07 | — | — | EP | disclosed |
| US-9550739-B2 | Molecules having certain pesticidal utilities, and intermediates, compositions, and processes related thereto | DOW AGROSCIENCES LLC (US) | 2017-01-24 | — | — | US | disclosed |
| WO-2003015715-A2 | TETRAHYDROQUINOLINE DERIVATIVES AS ANTITHROMBOTIC AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-02-27 | — | — | WO | disclosed |
| CN-1080257-C | Guanidine derivatives as inhibitors of Na+/H+ exchange in cells | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-03-06 | — | — | CN | disclosed |
| EP-0699185-B1 | GUANIDINE DERIVATIVES AS INHIBITORS OF Na+ /H+ EXCHANGE IN CELLS | FUJISAWA PHARMACEUTICAL CO (JP) | 2001-09-05 | — | — | EP | disclosed |
| US-5824691-A | CARDIOVASCULAR, CEREBROVASCULAR, RENAL DISEASES; SHOCK, ARTERIOSCLEROSIS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-10-20 | — | — | US | disclosed |
| EP-0758243-A4 | BINDING OF E-SELECTIN, P-SELECTIN OR L-SELECTIN TO SIALYL-LEWISx OR SIALYL-LEWISa | TEXAS BIOTECHNOLOGY CORP (US) | 1997-08-20 | — | — | EP | disclosed |
| EP-0758243-A1 | BINDING OF E-SELECTIN, P-SELECTIN OR L-SELECTIN TO SIALYL-LEWISx OR SIALYL-LEWISa | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1997-02-19 | — | — | EP | disclosed |
| CN-1123545-A | Guanidine derivatives as inhibitors of Na+/H+ exchange in cells | FUJISAWA PHARMACEUTICAL CO (JP) | 1996-05-29 | — | — | CN | disclosed |
| EP-0699185-A1 | GUANIDINE DERIVATIVES AS INHIBITORS OF Na+ /H+ EXCHANGE IN CELLS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-03-06 | — | — | EP | disclosed |
| WO-1995029682-A1 | BINDING OF E-SELECTIN, P-SELECTIN OR L-SELECTIN TO SIALYL-LEWISx OR SIALYL-LEWIS?a¿ | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1995-11-09 | — | — | WO | disclosed |
| WO-1994026709-A1 | GUANIDINE DERIVATIVES AS INHIBITORS OF Na+/H+ EXCHANGE IN CELLS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001846-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | BCL2, BCL2A1, BAX | KAT6A 3183/4885PTGER1 94/4885KMO 4210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.